VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium -

Core Viewpoint - VolitionRx Limited has secured an additional €2.0 million (approximately $2.3 million) in financing to support its manufacturing capabilities and research and development efforts in Wallonia, Belgium [1][2]. Financing and Support - The financing was provided by Namur Invest and Wallonie Entreprendre S.A., highlighting their commitment to supporting innovative companies like Volition [1][2]. - This funding is part of Volition's strategy to seek non-dilutive funding, bringing the total non-dilutive funding to over $25 million to date [4]. Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics, aiming to improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [4][5]. - The company is developing cost-effective blood tests for detecting and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [5]. Research and Development - Volition's R&D activities are primarily based in Belgium, with additional facilities in the U.S. and London [6].